through separate high-affinity binding sites, with tubulin, the subunit protein of microtubules (Wilson et al., 1975; Olmsted & Borisy, 1973) . Further, colchicine-binding studies in subcellular fractions from mammalian brain provide indirect evidence that tubulin is firmly associated with isolated synaptic junctional complexes, as well as being present in perikaryal and synaptosomal soluble fractions (for references, see Lagnado et ul., 1975) . This was corroborated by more direct evidence based on chemical analysis of purified synaptic-junctional fractions enriched in post-synaptic density material (Walters & Matus, 1975) and by immunohistochemical (Matus et al., 1975) and electronmicroscopic observations (Gray, 1975) on cerebral-cortex tissue in situ.
Taken together, these observations suggest that some of the observed pharmacological effects of anti-tubulin drugs on synaptic function (see, e.g., Katz, 1972; Hanbauer et ul. 1974; Wooten et al., 1975; Poisner, 1973; Sorimachi et al., 1973) may be related to a direct interaction of the drugs with tubulin associated with synaptic components. To investigate further this possibility, the distribution of colchicine-and vinblastine-binding sites in subcellular fractions from chick brain was studied, with particular reference to subfractions derived from synaptosomes.
Whole brain from 1-3-day-old chicks was homogenized and fractionated by the method of Jones & Matus (1974) , except that 2mhl-sodium phosphate buffer, pH6.8, and 5Op~-MgCl, was incorporated into the sucrose solutions used throughout. The crude mitochondrial pellet (P,) was lysed for 30min at 4°C in 2rnhl-sodium phosphate buffer, pH8.1, and spun at 1000OOga,. for 30min to extract the synaptosol (Pz-sol), before further subfractionation of the particulate material. The crude post-mitochondria1 supernatant (S,) was spun at 1000OOga,. for 60min to yield a crude microsomal (P3) and soluble (SB) fraction. Colchicine-binding activity was assayed in freshly obtained fractions as previously described (Lagnado et al., 1971) , except that vinblastine ( I O O~~M , final concn.) was incorporated in the assay mixtures which contained 200-400pg of protein in a final volume of 0.5 ml. Vinblastine binding was assayed in a similar manner (Owellen et al., 1974) , by using 5p~-[G-~H]vinblastine sulphate (sp. radioactivity, 30Ci/mol; The Radiochemical Centre, Amersham, Bucks., U.K. ; batch 1).
The results summarized in Table 1 show that the distribution of binding activities for both drugs in subfractions of the postnuclear (S2, P2) and postmitochondrial (S3, P3)
supernatants (S, and S2, respectively) were very similar and that for each drug, only a slight enrichment in binding activity was seen in the respective soluble fractions obtained (Table 1 , last two columns). By contrast, marked differences were observed in the relative distributions of binding activities among the subfractions derived from the lysed crude mitochondrial fraction. The distribution of colchicine-binding sites was similar to that found previously for mammalian brain (Lagnado et al., 1971) , showing a relative enrichment in the synaptosol and synaptic-membrane-enriched fractions, but relatively little activity in other fractions. Vinblastine-binding sites, on the other hand, were concentrated primarily in the myelin fraction, which also contains light membranes, whose origin has not been determined. It may be noteworthy, in this connection, that although vinblastine stabilized colchicine-binding activity in the synaptosol and synaptic-plasma-membrane fractions, colchicine binding in the myelin fraction was consistently inhibited by about 20 % in the presence of 100pM-vinbIastine (A. N. Itani, unpublished work). In addition, the fraction containing synaptic plasma membranes was Further work is clearly required t o establish whether the differences observed in the distribution of colchicine-and vinblastine-binding activities among subsynaptosomal components are related t o intrinsic differences in the nature of the receptors involved, or t o other factors which might differentially affect the binding reactions for the two drugs. The possibility that Vincaalkaloids can also interact withnon-tubdin components in other tissues has already been noted (see, e.g., Wilson et al., 1970) . In conclusion, it is evident that some caution is needed in interpreting the observed effects of antimitotic alkaloids on neural function as resulting initially, from a direct interaction with micro-
